CytoCore Provides 2007 Financial Guidance.

Company Anticipates Reaching Break-Even With Existing Reserves

CHICAGO -- CytoCore (OTCBB:CYCR), the late-stage bio-pharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, today announced improved financial guidance based on Q1-07 activities.

CytoCore has raised approximately $4 million in equity during the first quarter 2007 and has settled all claims that had originated from outstanding law suits. With the anticipated conversion of debt into equity, CytoCore will have less than $3 million in liabilities and expects that by mid-year 2007 this balance will reflect only current trade payables of approximately $1.5 million. The company expects that less than one-third of the anticipated reduction in liabilities will require the use of cash.

With $3.7 million in cash reserves, and another $1.3 million committed by early fall, management believes that CytoCore has sufficient resources to get to cash-flow break-even based upon projected sales. Also, CEO Augusto Ocana exercised a warrant to purchase 500,000 shares.

CytoCore's CFO, Robert McCullough, stated: "We continue to keep our administrative and general expenses running lean to ensure that our resources remain focused on patient trials, research, product development and marketing initiatives. We are very pleased with the progress we've made over the past year and believe that we will continue to make further progress toward profitability. We are anticipating the sales launch of the e2 Collector[TM] later in 2007 and are currently ramping up volume production capabilities to meet our financial objectives."

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.